doi:10.19982/j.issn.1000-6621.20240104

Abstract

CLC Number:

Figures/Tables 4

References 20

[1]	戴广川, 尹春阳, 陈珊珊, 等. 结节病与结核病共病一例. 中国防痨杂志, 2022, 44(11): 1222-1226. doi:10.19982/j.issn.1000-6621.20220270.
[2]	Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016, 63(4): e1-e60. doi:10.1093/cid/ciw326.
[3]	Sato S, Kamata W, Fukaguchi K, et al. Successful treatment of invasive tracheobronchial pulmonary aspergillosis with venovenous extracorporeal membrane oxygenation and combined systemic, intratracheal instillation of liposomal amphotericin B: a case report. J Med Case Rep, 2022, 16(1): 470. doi:10.1186/s13256-022-03692-1.
[4]	Nyga R, Maizel J, Nseir S, et al. Invasive Tracheobronchial Aspergillosis in Critically Ill Patients with Severe Influenza. A Clinical Trial. Am J Respir Crit Care Med, 2020, 202(5): 708-716. doi:10.1164/rccm.201910-1931OC.
[5]	Pak C, Jo W, Kim JH, et al. Differences in Clinical Characteristics of Invasive Tracheobronchial Aspergillosis according to the Presence of Invasive Pulmonary Aspergillosis. Tuberc Respir Dis (Seoul), 2021, 84(4): 326-332. doi:10.4046/trd.2021.0029.
[6]	Buonomo AR, Viceconte G, Compare D, et al. Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn’s disease. IDCases, 2019, 17: e00537. doi:10.1016/j.idcr.2019.e00537.
[7]	Hosseini M, Shakerimoghaddam A, Ghazalibina M, et al. Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa countries; A systematic review and meta-analysis of cross-sectional studies. Microb Pathog, 2020, 141: 104018. doi:10.1016/j.micpath.2020.104018.
[8]	Moldoveanu B, Gearhart AM, Jalil BA, et al. Pulmonary Aspergillosis: Spectrum of Disease. Am J Med Sci, 2021, 361(4): 411-419. doi:10.1016/j.amjms.2020.12.009. pmid: 33563417
[9]	Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am, 2006, 20(3): 545-561, vi. doi:10.1016/j.idc.2006.06.001.
[10]	Cho JS, Kim JJ, Jeong SY, et al. Pseudomembranous Aspergillus Tracheobronchitis: Case Report of a Rare Manifestation of Airway Invasive Aspergillosis. Taehan Yongsang Uihakhoe Chi, 2022, 83(3): 737-743. doi:10.3348/jksr.2021.0091.
[11]	田瑶, 刘辉敏, 傅满姣, 等. 结核病与糖尿病共病诊疗现状. 结核与肺部疾病杂志, 2022, 3(2): 91-95. doi:10.19983/j.issn.2096-8493.20210111.
[12]	Lu P, Zhang Y, Liu Q, et al. Association of BMI, diabetes, and risk of tuberculosis: a population-based prospective cohort. Int J Infect Dis, 2021, 109: 168-173. doi:10.1016/j.ijid.2021.06.053. pmid: 34217872
[13]	Ghanaat F, Tayek JA. Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non-immunocompromized humans. Clin Pract (Lond), 2017, 14(5 Spec Iss): 296-301. doi:10.4172/clinical-practice.1000125.
[14]	梁嫄琦, 李鸿茹, 黄丽萍, 等. 肺真菌病78例临床分析. 中国感染与化疗杂志, 2018, 18(3): 252-257. doi:10.16718/j.1009-7708.2018.03.002.
[15]	Ohta H, Yamazaki S, Miura Y, et al. Invasive tracheobronchial aspergillosis progressing from bronchial to diffuse lung parenchymal lesions. Respirol Case Rep, 2016, 4(1): 32-34. doi:10.1002/rcr2.144.
[16]	Wu N, Huang Y, Li Q, et al. Isolated invasive Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol Infect, 2010, 16(6): 689-695. doi:10.1111/j.1469-0691.2009.02923.x.
[17]	中华医学会结核病学分会, 结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6): 419-425. doi:10.3760/cma.j.issn.1001-0939.2017.06.005.
[18]	黄丹, 王璞. 肉芽肿性肺疾病的研究现状. 医学信息, 2022, 35(5): 44-48. doi:10.3969/j.issn.1006-1959.2022.05.011.
[19]	Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother, 2001, 45(2): 382-392. doi:10.1128/AAC.45.2.382-392.2001.
[20]	Hagiya H, Miyake T, Kokumai Y, et al. Co-infection with invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonia after corticosteroid therapy. J Infect Chemother, 2013, 19(2): 342-347. doi:10.1007/s10156-012-0473-9. pmid: 22965844

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 20

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.